Acquisition Corp Tyto serves as Executive at Prevail Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, Acquisition Corp Tyto has executed 1 insider transactions totaling $771.4M, demonstrating a bullish approach to their equity position. Their most recent transaction on Jan 22, 2021 involved purchasing 34,284,789 shares valued at $771.4M.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 22, 2021 | PRVL | $771.4M | Purchase | 34,284,789 | $22.50 | Discretionary |
Acquisition Corp Tyto currently holds 100 shares of Prevail Therapeutics Inc. (PRVL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Acquisition Corp Tyto has been a net buyer of PRVL stock. They have purchased $771.4M and sold $0 worth of shares.
Acquisition Corp Tyto's most recent insider trade was on Jan 22, 2021, when they purchased 34,284,789 shares at $22.50 per share.
Get notified when new Form 4 filings are submitted